Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies

NCT04824794 is registered in ClinicalTrials.gov with Genmab as lead sponsor.

NCT NCT04824794
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04824794 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
Lead sponsor
Genmab
Phase
Phase 1/2
Overall status
Terminated
Start date
March 9, 2021
Completion date
July 31, 2025
Enrollment
130 (actual)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml), diffuse large b cell lymphoma (dlbcl), relapsed or refractory multiple myeloma (rrmm)